OS Therapies Inc. - 10-Q Filing Summary (Q3 2025)
Business Context and Reporting Period
Company: OS Therapies Inc. (OSTX)
Reporting Period: Quarter ended September 30, 2025 (Q3 2025) and nine months ended September 30, 2025.
Business Overview: A clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma and other solid tumors. The lead product candidate is OST-HER2. The company operates as a single segment and is classified as an Emerging Growth Company and Smaller Reporting Company.
Key Milestone: In October 2025, the company announced final two-year overall survival data from its Phase IIb trial showing 75% survival in treated patients versus 40% in historical controls.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(6,879,530) | $(2,875,232) | $(15,293,011) | $(5,891,704) |
| Loss Per Share (Basic & Diluted) | $(0.21) | $(0.18) | $(0.57) | $(0.64) |
| Cash and Cash Equivalents (End of Period) | $1,876,626 (as of Sept 30, 2025) | |||
| Total Assets | $8,953,251 (as of Sept 30, 2025) | |||
| Total Liabilities | $4,245,351 (as of Sept 30, 2025) | |||
| Stockholders' Equity | $3,637,195 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased significantly to $6.9 million for Q3 2025 from $2.4 million in Q3 2024.
- Research & Development (R&D): Rose to $3.8 million (Q3 2025) from $1.2 million (Q3 2024), driven by vendor expenses for the Phase IIb clinical trial and regulatory submissions.
- General & Administrative (G&A): Rose to $3.1 million (Q3 2025) from $1.2 million (Q3 2024), primarily due to marketing, investor relations, and advisory fees related to financing activities.
- Non-Cash Gains: The company recorded a gain of $1.4 million in the nine months ended Sept 30, 2025, due to the change in fair value of warrant liabilities, which were subsequently reclassified to equity following stockholder approval in April 2025. No such gain was recorded in the comparable 2024 period.
- Interest Expense: Interest expense was $0 for Q3 and YTD 2025, compared to $0.4 million and $2.0 million respectively in 2024, as all convertible notes were converted to equity in August 2024.
- Asset Acquisition: In April 2025, the company acquired HER2 Assets from Ayala Pharmaceuticals for a total consideration of approximately $6.9 million (cash and stock), adding $6.6 million in net patents to the balance sheet.
Guidance, Outlook, Risks, and Unusual Items
- Regulatory Outlook: Management expects to submit a conditional Marketing Authorization Application (MAA) to the UK MHRA in December 2025, a Biologics License Application (BLA) to the FDA in January 2026, and an MAA to the EMA in Q1 2026.
- Liquidity and Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern. Cash on hand is approximately $1.9 million, and the company estimates it can fund operations for the next 9 to 12 months. Continued operations depend on raising additional capital.
- Financing Activities:
- PIPE Financing: Raised ~$7.1 million in late 2024/early 2025 via Series A Preferred Stock and Warrants.
- Warrant Inducement: Raised ~$6.4 million in Q3 2025 through warrant exercise inducement offers.
- ATM Program: Initiated an "At-The-Market" equity offering program in August 2025 with a capacity of up to $18 million. As of the filing date, $384,888 had been raised.
- Legal Proceedings: The company is awaiting a ruling on an arbitration claim from a former investment advisor regarding underwriter compensation. A resolution is expected in February 2026.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to a lack of segregation of duties and insufficient written policies.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.9 million cash balance against the projected burn rate of ~$7 million per quarter to confirm the 9-12 month runway estimate.
- Regulatory Timeline: Monitor the submission dates for the MHRA (Dec 2025) and FDA (Jan 2026) applications and the release of biomarker data expected in November 2025.
- Dilution Risk: Assess the impact of the ATM program ($18M capacity), outstanding warrants (~9.5 million shares), and options (~2.7 million shares) on future share count.
- Arbitration Outcome: Track the February 2026 ruling on the former investment advisor's claim for potential financial liability.
- Internal Controls Remediation: Review future filings for updates on the remediation of the material weakness in internal controls over financial reporting.